FOLLITROPIN

FOLLITROPIN was reported 2046 times

FOLLITROPIN is most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 BLOOD HUMAN CHORIONIC GONADOTROPIN NEGATIVE 1 0.5000
1 ULTRASOUND SCAN VAGINA ABNORMAL 1 0.1429
2 OPTIC NERVE SHEATH MENINGIOMA 3 0.1364
3 ASSISTED FERTILISATION 1 0.1250
4 POOR RESPONSE TO OVULATION INDUCTION 1 0.0909
5 OVULATION INDUCTION 1 0.0769
6 OVARIAN HYPERSTIMULATION SYNDROME 43 0.0184
7 FAILED IN VITRO FERTILISATION 1 0.0164
8 NIPPLE ENLARGEMENT 1 0.0161
9 ECTOPIC PREGNANCY TERMINATION 1 0.0159
10 OVARIAN NECROSIS 1 0.0159
11 PREMATURE OVULATION 1 0.0128
12 OVARIAN TORSION 1 0.0120
13 BLOOD VISCOSITY ABNORMAL 1 0.0105
14 UTERINE HYPERSTIMULATION 1 0.0098
15 BIOCHEMICAL PREGNANCY 1 0.0093
16 POOR QUALITY DEVICE USED 91 0.0091
17 PROGESTERONE INCREASED 1 0.0090
18 BLOOD LUTEINISING HORMONE INCREASED 2 0.0081
19 APPLICATION SITE NODULE 1 0.0073
20 VACTERL SYNDROME 1 0.0071
21 CONGENITAL CHOROID PLEXUS CYST 2 0.0066
22 TINEA VERSICOLOUR 2 0.0056
23 IN VITRO FERTILISATION 1 0.0055
24 OVARIAN DISORDER 5 0.0053
25 INJECTION SITE ECZEMA 1 0.0052
26 ANOVULATORY CYCLE 1 0.0048
27 BLOOD HUMAN CHORIONIC GONADOTROPIN INCREASED 1 0.0047
28 ARNOLD-CHIARI MALFORMATION 4 0.0042
29 PELVIC ADHESIONS 1 0.0042
30 TUBO-OVARIAN ABSCESS 1 0.0041
31 EXPOSURE TO CONTAMINATED DEVICE 1 0.0038
32 HAEMORRHAGIC OVARIAN CYST 2 0.0035
33 NIPPLE DISORDER 2 0.0032
34 PROGESTERONE DECREASED 1 0.0032
35 PROTEIN DEFICIENCY 1 0.0032
36 SALPINGITIS 1 0.0031
37 MATERNAL EXPOSURE BEFORE PREGNANCY 21 0.0031
38 ENTEROBACTER SEPSIS 1 0.0027
39 OVARIAN ENLARGEMENT 1 0.0026
40 RUPTURED ECTOPIC PREGNANCY 2 0.0026
41 LIPOEDEMA 1 0.0025
42 ENDOMETRIAL HYPERTROPHY 1 0.0025
43 GASTROINTESTINAL ANGIODYSPLASIA 1 0.0024
44 TWIN PREGNANCY 2 0.0024
45 THREATENED LABOUR 1 0.0023
46 HUMAN CHORIONIC GONADOTROPIN INCREASED 2 0.0022
47 PREGNANCY TEST FALSE POSITIVE 1 0.0021
48 DRAINAGE 1 0.0020
49 ABORTION THREATENED 1 0.0020
50 DRUG EXPOSURE BEFORE PREGNANCY 2 0.0020
51 ECTOPIC PREGNANCY 6 0.0019
52 SPINA BIFIDA 4 0.0019
53 DEVICE USE CONFUSION 1 0.0019
54 OVARIAN FAILURE 1 0.0019
55 MORNING SICKNESS 1 0.0018
56 ANENCEPHALY 1 0.0018
57 BREAST DISCHARGE 3 0.0017
58 BLOOD OESTROGEN INCREASED 1 0.0017
59 CIRCUMSTANCE OR INFORMATION CAPABLE OF LEADING TO DEVICE USE ERROR 4 0.0017
60 HYPERCOAGULATION 3 0.0016
61 GASTROINTESTINAL MUCOSAL DISORDER 1 0.0015
62 CIRCUMSTANCE OR INFORMATION CAPABLE OF LEADING TO MEDICATION ERROR 51 0.0015
63 LEIOMYOMA 1 0.0014
64 POOR QUALITY PRODUCT ADMINISTERED 15 0.0014
65 PELVIC FLUID COLLECTION 1 0.0014
66 HEMIANOPIA HOMONYMOUS 1 0.0014
67 PRODUCT LEAKAGE 7 0.0012
68 SEPSIS NEONATAL 1 0.0012
69 VULVOVAGINAL ERYTHEMA 1 0.0012
70 CAROTID ARTERY THROMBOSIS 1 0.0012
71 INTENTIONAL DEVICE USE ISSUE 1 0.0012
72 CHOROIDAL NEOVASCULARISATION 1 0.0012
73 ABSCESS DRAINAGE 1 0.0012
74 ADVERSE FOOD REACTION 1 0.0011
75 PELVIC DISCOMFORT 1 0.0011
76 EXPOSURE VIA DIRECT CONTACT 1 0.0011
77 MESENTERIC VEIN THROMBOSIS 1 0.0010
78 NIPPLE PAIN 2 0.0010
79 NO ADVERSE EVENT 176 0.0010
80 NON-CARDIOGENIC PULMONARY OEDEMA 1 0.0009
81 INCORRECT DOSE ADMINISTERED BY DEVICE 23 0.0009
82 DEVICE DISPENSING ERROR 1 0.0008
83 PRODUCT PACKAGING ISSUE 8 0.0008
84 VAGINAL ODOUR 1 0.0008
85 PRODUCT CONTAMINATION PHYSICAL 2 0.0008
86 ADNEXA UTERI PAIN 1 0.0008
87 OVARIAN CYST RUPTURED 1 0.0008
88 CALCIUM DEFICIENCY 1 0.0008
89 ABDOMINAL DISTENSION 80 0.0008
90 BREAST SWELLING 2 0.0007
91 PRODUCT DELIVERY MECHANISM ISSUE 4 0.0007
92 EFFUSION 1 0.0007
93 INJECTION SITE HYPOAESTHESIA 1 0.0007
94 HAEMORRHAGIC TRANSFORMATION STROKE 1 0.0007
95 ADHESION 1 0.0007
96 RUBBER SENSITIVITY 1 0.0007
97 POLYCYSTIC OVARIES 1 0.0006
98 INFERTILITY FEMALE 1 0.0006
99 INJECTION SITE HYPERSENSITIVITY 2 0.0006
100 BACTERIAL VAGINOSIS 1 0.0006
101 DEVICE DEFECTIVE 11 0.0006
102 INCORRECT DOSE ADMINISTERED BY PRODUCT 1 0.0006
103 DEVICE MALFUNCTION 43 0.0006
104 EXPIRED DEVICE USED 2 0.0006
105 DEVICE LEAKAGE 26 0.0006
106 SLEEP TALKING 1 0.0006
107 BLOOD CHLORIDE INCREASED 1 0.0006
108 PRODUCT TAMPERING 1 0.0006
109 NEEDLE ISSUE 16 0.0005
110 MATERNAL EXPOSURE TIMING UNSPECIFIED 2 0.0005
111 BREAST TENDERNESS 4 0.0005
112 PRODUCT QUALITY ISSUE 69 0.0005
113 DEVICE MATERIAL ISSUE 1 0.0005
114 OPTIC NEUROPATHY 1 0.0005
115 EAR SWELLING 1 0.0005
116 INJECTION SITE IRRITATION 6 0.0005
117 ANAEMIA MACROCYTIC 1 0.0005
118 PRODUCT DISPENSING ISSUE 2 0.0005
119 VULVOVAGINAL DISCOMFORT 2 0.0005
120 PRODUCT LOT NUMBER ISSUE 1 0.0005
121 HAEMATOCRIT INCREASED 1 0.0004
122 ABORTION SPONTANEOUS 17 0.0004
123 INJECTION SITE REACTION 29 0.0004
124 ENDOMETRIOSIS 2 0.0004
125 LIQUID PRODUCT PHYSICAL ISSUE 3 0.0004
126 EYE OEDEMA 1 0.0004
127 EXPIRED DRUG ADMINISTERED 2 0.0004
128 INJECTION SITE ABSCESS 1 0.0004
129 LACTOSE INTOLERANCE 1 0.0004
130 EAR CONGESTION 1 0.0004
131 NORMAL NEWBORN 2 0.0004
132 LIP BLISTER 1 0.0004
133 THYROID NEOPLASM 1 0.0004
134 MENSTRUAL DISORDER 3 0.0004
135 MATERNAL EXPOSURE DURING PREGNANCY 32 0.0004
136 INJECTION SITE RASH 11 0.0004
137 INJECTION SITE PRURITUS 24 0.0004
138 INJECTION SITE SCAR 1 0.0004
139 HOT FLUSH 26 0.0003
140 AUTONOMIC NERVOUS SYSTEM IMBALANCE 1 0.0003
141 INJECTION SITE BRUISING 27 0.0003
142 EMERGENCY CARE 1 0.0003
143 FOETAL GROWTH RESTRICTION 2 0.0003
144 DEVICE BREAKAGE 13 0.0003
145 OCCUPATIONAL EXPOSURE TO PRODUCT 2 0.0003
146 LOOSE TOOTH 1 0.0003
147 POLYP 2 0.0003
148 OVARIAN CYST 3 0.0003
149 WRONG PRODUCT ADMINISTERED 2 0.0003
150 PRODUCT LABEL ISSUE 2 0.0003
151 INCORRECT DOSE ADMINISTERED 67 0.0003
152 HAIR GROWTH ABNORMAL 2 0.0003
153 INJECTION SITE DISCOMFORT 3 0.0003
154 BREAST PAIN 3 0.0003
155 PRODUCT CONTAMINATION 1 0.0003
156 PRODUCT SUPPLY ISSUE 2 0.0003
157 HYPERTHYROIDISM 4 0.0003
158 UTERINE LEIOMYOMA 2 0.0003
159 BLINDNESS TRANSIENT 2 0.0003
160 INJECTION SITE MASS 10 0.0003
161 PROTEIN TOTAL DECREASED 1 0.0003
162 AUTOIMMUNE THYROIDITIS 1 0.0003
163 MATERNAL DRUGS AFFECTING FOETUS 2 0.0003
164 SUSPECTED COUNTERFEIT PRODUCT 1 0.0003
165 MOOD SWINGS 8 0.0003
166 MUSCLE HAEMORRHAGE 1 0.0002
167 CYST 3 0.0002
168 PRODUCT STORAGE ERROR 21 0.0002
169 WRONG TECHNIQUE IN DEVICE USAGE PROCESS 11 0.0002
170 INCORRECT DRUG ADMINISTRATION RATE 1 0.0002
171 POOR PERIPHERAL CIRCULATION 1 0.0002
172 PRODUCT CONTAINER ISSUE 2 0.0002
173 DEVICE OPERATIONAL ISSUE 1 0.0002
174 CHAPPED LIPS 1 0.0002
175 PRODUCT PRESCRIBING ISSUE 5 0.0002
176 ADVERSE REACTION 3 0.0002
177 PRODUCT AVAILABILITY ISSUE 5 0.0002
178 HAEMOGLOBIN INCREASED 1 0.0002
179 INJECTION SITE PAPULE 1 0.0002
180 INJECTION SITE ERYTHEMA 27 0.0002
181 PRODUCT DOSE OMISSION 14 0.0002
182 SKIN TIGHTNESS 1 0.0002
183 EXPOSURE DURING PREGNANCY 13 0.0002
184 VAGINAL HAEMORRHAGE 9 0.0002
185 STILLBIRTH 1 0.0002
186 INJECTION SITE PAIN 63 0.0002
187 INCORRECT DOSAGE ADMINISTERED 1 0.0002
188 INJECTION SITE URTICARIA 5 0.0002
189 SMALL FOR DATES BABY 1 0.0002
190 APPLICATION SITE SWELLING 1 0.0002
191 PREGNANCY 4 0.0002
192 VAGINAL DISCHARGE 2 0.0002
193 VULVOVAGINAL PRURITUS 1 0.0002
194 THYROID DISORDER 3 0.0002
195 CEREBRAL ISCHAEMIA 1 0.0002
196 EXPOSURE VIA SKIN CONTACT 5 0.0002
197 HEADACHE 120 0.0002
198 CHEILITIS 1 0.0002
199 PRODUCT DOSE OMISSION ISSUE 54 0.0002
200 MOOD ALTERED 5 0.0002
201 DEVICE DIFFICULT TO USE 12 0.0002
202 NECROSIS 1 0.0002
203 INTERMENSTRUAL BLEEDING 1 0.0002
204 INCORRECT ROUTE OF PRODUCT ADMINISTRATION 3 0.0002
205 CAESAREAN SECTION 2 0.0002
206 PROTHROMBIN TIME PROLONGED 1 0.0002
207 TYPE 1 DIABETES MELLITUS 1 0.0002
208 INJECTION SITE DISCOLOURATION 2 0.0002
209 DERMATITIS ALLERGIC 2 0.0002
210 BLEPHAROSPASM 1 0.0002
211 THERAPEUTIC RESPONSE CHANGED 1 0.0002
212 POOR QUALITY DRUG ADMINISTERED 1 0.0002
213 SLEEP DISORDER DUE TO GENERAL MEDICAL CONDITION, INSOMNIA TYPE 1 0.0002
214 BRADYPHRENIA 1 0.0002
215 PRODUCT PREPARATION ISSUE 1 0.0002
216 LIP SWELLING 5 0.0001
217 PRODUCT ADMINISTRATION ERROR 3 0.0001
218 INJURY ASSOCIATED WITH DEVICE 3 0.0001
219 DEVICE ISSUE 13 0.0001
220 HYPERTRANSAMINASAEMIA 1 0.0001
221 CEREBRAL DISORDER 1 0.0001
222 HYPOAESTHESIA ORAL 2 0.0001
223 PEMPHIGOID 1 0.0001
224 APPLICATION SITE PRURITUS 3 0.0001
225 DEVICE PHYSICAL PROPERTY ISSUE 1 0.0001
226 EMOTIONAL DISORDER 4 0.0001
227 AFFECTIVE DISORDER 1 0.0001
228 BLOOD ALBUMIN DECREASED 1 0.0001
229 RASH ERYTHEMATOUS 6 0.0001
230 BLOOD DISORDER 1 0.0001
231 CONTUSION 12 0.0001
232 MUSCLE DISORDER 1 0.0001
233 EMBOLISM 1 0.0001
234 INJECTION SITE SWELLING 9 0.0001
235 MIGRAINE 11 0.0001
236 DEVICE USE ISSUE 2 0.0001
237 NAIL DISORDER 1 0.0001
238 PRODUCT COMMUNICATION ISSUE 1 0.0001
239 HAEMARTHROSIS 1 0.0001
240 OROPHARYNGEAL DISCOMFORT 1 0.0001
241 LIP DRY 1 0.0001
242 HIDRADENITIS 1 0.0001
243 PRODUCT ADMINISTERED AT INAPPROPRIATE SITE 2 0.0001
244 ADVERSE EVENT 10 0.0001
245 LEUKAEMIA 1 0.0001
246 PRODUCT DOSE OMISSION IN ERROR 3 0.0001
247 URTICARIA 17 0.0001
248 EAR DISCOMFORT 1 0.0001
249 INJECTION SITE WARMTH 2 0.0001
250 TENDERNESS 1 0.0001
251 POOR QUALITY SLEEP 2 0.0001
252 MUSCLE SPASMS 17 0.0001
253 PRODUCT DISPENSING ERROR 2 0.0001
254 OESOPHAGITIS 1 0.0001
255 SCAB 1 0.0001
256 ACCIDENTAL EXPOSURE TO PRODUCT 9 0.0001
257 FATIGUE 67 0.0001
258 BURNING SENSATION 6 0.0001
259 SWELLING 8 0.0001
260 DRUG DOSE OMISSION 14 0.0001
261 CHOLECYSTITIS 1 0.0001
262 IRRITABILITY 5 0.0001
263 CRYING 3 0.0001
264 ACCIDENTAL OVERDOSE 3 0.0001
265 PRURITUS 31 0.0001
266 TOOTH EXTRACTION 1 0.0001
267 DEVICE DEPLOYMENT ISSUE 1 0.0001
268 INTRAOCULAR PRESSURE INCREASED 1 0.0001
269 CONSTIPATION 17 0.0001
270 HIATUS HERNIA 1 0.0001
271 NAUSEA 61 0.0001
272 PLATELET COUNT INCREASED 1 0.0001
273 NODULE 1 0.0001
274 APPLICATION SITE ERYTHEMA 2 0.0001
275 INCORRECT PRODUCT STORAGE 1 0.0001
276 GASTRITIS 2 0.0001
277 DYSMENORRHOEA 1 0.0001
278 FEAR 2 0.0001
279 SINUS CONGESTION 1 0.0001
280 THROAT TIGHTNESS 2 0.0001
281 FOETAL EXPOSURE DURING PREGNANCY 6 0.0001
282 LIMB INJURY 2 0.0001
283 RASH 32 0.0001
284 GINGIVAL BLEEDING 1 0.0001
285 PERIPHERAL COLDNESS 1 0.0001
286 ABNORMAL DREAMS 2 0.0001
287 DISSEMINATED INTRAVASCULAR COAGULATION 1 0.0001
288 BLINDNESS UNILATERAL 1 0.0001
289 PARAESTHESIA ORAL 1 0.0001
290 ASCITES 2 0.0001
291 DRUG EFFECT LESS THAN EXPECTED 1 0.0001
292 CONTRAINDICATED PRODUCT ADMINISTERED 2 0.0001
293 DISCOMFORT 4 0.0001
294 MUSCULOSKELETAL CHEST PAIN 1 0.0001
295 SWOLLEN TONGUE 2 0.0001
296 BRAIN FOG 1 0.0001
297 PRODUCT USE COMPLAINT 1 0.0001
298 PNEUMOTHORAX 1 0.0001
299 NIGHT SWEATS 2 0.0001
300 MUSCLE TIGHTNESS 1 0.0001
301 BLOOD POTASSIUM INCREASED 1 0.0001
302 CHOLELITHIASIS 2 0.0001
303 FUNGAL INFECTION 2 0.0001
304 BLOOD UREA INCREASED 1 0.0001
305 ANGER 2 0.0001
306 SLEEP DISORDER DUE TO A GENERAL MEDICAL CONDITION 1 0.0001
307 METRORRHAGIA 1 0.0001
308 THERAPY CESSATION 3 0.0001
309 SCAR 1 0.0001
310 PARANOIA 1 0.0001
311 ORTHOSTATIC HYPOTENSION 1 0.0001
312 SYRINGE ISSUE 1 0.0001
313 PRODUCT USE IN UNAPPROVED INDICATION 14 0.0001
314 TACHYCARDIA 5 0.0001
315 THIRST 1 0.0001
316 RASH PRURITIC 3 0.0001
317 RESTLESS LEGS SYNDROME 1 0.0001
318 BONE DISORDER 1 0.0001
319 UNDERDOSE 4 0.0001
320 ABDOMINAL DISCOMFORT 9 0.0001
321 BLOOD SODIUM DECREASED 1 0.0001
322 FEELING JITTERY 1 0.0001
323 SLEEP APNOEA SYNDROME 1 0.0001
324 LOWER LIMB FRACTURE 1 0.0001
325 PRESCRIBED OVERDOSE 1 0.0001
326 EAR PAIN 1 0.0001
327 ORAL HERPES 1 0.0001
328 DRUG DOSE OMISSION BY DEVICE 4 0.0001
329 MENORRHAGIA 1 0.0001
330 PRESCRIBED UNDERDOSE 1 0.0001
331 WEIGHT INCREASED 11 0.0000
332 FEELING HOT 3 0.0000
333 DIZZINESS 24 0.0000
334 KNEE ARTHROPLASTY 1 0.0000
335 HYPOACUSIS 2 0.0000
336 DEEP VEIN THROMBOSIS 3 0.0000
337 INCORRECT PRODUCT ADMINISTRATION DURATION 1 0.0000
338 SWELLING FACE 3 0.0000
339 GAMMA-GLUTAMYLTRANSFERASE INCREASED 1 0.0000
340 RASH PAPULAR 1 0.0000
341 WRONG TECHNIQUE IN PRODUCT USAGE PROCESS 9 0.0000
342 ABDOMINAL PAIN UPPER 9 0.0000
343 SKIN IRRITATION 2 0.0000
344 NEPHROLITHIASIS 2 0.0000
345 LOCALISED INFECTION 1 0.0000
346 CEREBRAL INFARCTION 1 0.0000
347 LIVER INJURY 1 0.0000
348 VOMITING 19 0.0000
349 BLOOD ALKALINE PHOSPHATASE INCREASED 1 0.0000
350 ABDOMINAL PAIN LOWER 1 0.0000
351 FLUID RETENTION 2 0.0000
352 ABDOMINAL PAIN 9 0.0000
353 RESPIRATORY TRACT INFECTION 1 0.0000
354 DERMATITIS ATOPIC 2 0.0000
355 HYPERSENSITIVITY 7 0.0000
356 PAIN 23 0.0000
357 THROMBOSIS 3 0.0000
358 PAIN OF SKIN 1 0.0000
359 BLOOD BILIRUBIN INCREASED 1 0.0000
360 PALLOR 1 0.0000
361 DEVICE DELIVERY SYSTEM ISSUE 1 0.0000
362 VISION BLURRED 5 0.0000
363 ANAPHYLACTIC REACTION 2 0.0000
364 NECK PAIN 2 0.0000
365 INCORRECT DRUG ADMINISTRATION DURATION 1 0.0000
366 PALPITATIONS 4 0.0000
367 DRUG EFFECTIVE FOR UNAPPROVED INDICATION 1 0.0000
368 LABORATORY TEST ABNORMAL 1 0.0000
369 FEELING ABNORMAL 8 0.0000
370 PREMATURE BABY 1 0.0000
371 THERAPEUTIC RESPONSE DECREASED 2 0.0000
372 PLEURAL EFFUSION 2 0.0000
373 PERIPHERAL SWELLING 5 0.0000
374 LIMB DISCOMFORT 1 0.0000
375 PRODUCT USE ISSUE 6 0.0000
376 PARAESTHESIA 5 0.0000
377 DRUG INTERACTION 5 0.0000
378 HYPOTHYROIDISM 1 0.0000
379 DYSPEPSIA 3 0.0000
380 STAPHYLOCOCCAL INFECTION 1 0.0000
381 EXPIRED PRODUCT ADMINISTERED 1 0.0000
382 SKIN DISORDER 1 0.0000
383 GAIT INABILITY 1 0.0000
384 SOMNOLENCE 6 0.0000
385 EYE PRURITUS 1 0.0000
386 FLUSHING 3 0.0000
387 DIARRHOEA 19 0.0000
388 DRUG EXPOSURE DURING PREGNANCY 1 0.0000
389 CHEST DISCOMFORT 3 0.0000
390 ERYTHEMA 6 0.0000
391 RASH MACULAR 1 0.0000
392 COVID-19 5 0.0000
393 INAPPROPRIATE SCHEDULE OF DRUG ADMINISTRATION 2 0.0000
394 THERAPY INTERRUPTED 2 0.0000
395 SKIN BURNING SENSATION 2 0.0000
396 WHITE BLOOD CELL COUNT DECREASED 3 0.0000
397 WRONG TECHNIQUE IN DRUG USAGE PROCESS 1 0.0000
398 DYSURIA 1 0.0000
399 CHEST PAIN 5 0.0000
400 EYE SWELLING 1 0.0000
401 HYPOAESTHESIA 4 0.0000
402 ACNE 2 0.0000
403 CHILLS 3 0.0000
404 INJECTION SITE HAEMORRHAGE 2 0.0000
405 POLLAKIURIA 1 0.0000
406 DRY SKIN 3 0.0000
407 ADVERSE DRUG REACTION 2 0.0000
408 INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION 4 0.0000
409 COGNITIVE DISORDER 1 0.0000
410 CARDIAC DISORDER 2 0.0000
411 PULMONARY EMBOLISM 2 0.0000
412 LOSS OF PERSONAL INDEPENDENCE IN DAILY ACTIVITIES 1 0.0000
413 HEART RATE INCREASED 2 0.0000
414 DRY EYE 1 0.0000
415 SYNCOPE 2 0.0000
416 SINUSITIS 2 0.0000
417 DYSPNOEA 11 0.0000
418 INFLAMMATION 1 0.0000
419 NERVOUSNESS 1 0.0000
420 ECZEMA 1 0.0000
421 MUSCULOSKELETAL PAIN 1 0.0000
422 DRUG INEFFECTIVE 25 0.0000
423 DEPRESSED MOOD 1 0.0000
424 ASPARTATE AMINOTRANSFERASE INCREASED 1 0.0000
425 INSOMNIA 5 0.0000
426 DRUG EFFECT DECREASED 1 0.0000
427 DRUG INEFFECTIVE FOR UNAPPROVED INDICATION 1 0.0000
428 MEDICATION ERROR 1 0.0000
429 COUGH 5 0.0000
430 BLISTER 1 0.0000
431 MYALGIA 3 0.0000
432 FLATULENCE 1 0.0000
433 RHEUMATOID ARTHRITIS 2 0.0000
434 MUSCULAR WEAKNESS 2 0.0000
435 ANXIETY 5 0.0000
436 LETHARGY 1 0.0000
437 EYE IRRITATION 1 0.0000
438 PYREXIA 6 0.0000
439 DECREASED APPETITE 4 0.0000
440 SURGERY 1 0.0000
441 ILL-DEFINED DISORDER 1 0.0000
442 VERTIGO 1 0.0000
443 ALANINE AMINOTRANSFERASE INCREASED 1 0.0000
444 RHINORRHOEA 1 0.0000
445 DEVICE EXPULSION 1 0.0000
446 PSORIASIS 2 0.0000
447 ALOPECIA 3 0.0000
448 DEHYDRATION 2 0.0000
449 HEPATIC ENZYME INCREASED 1 0.0000
450 INJURY 1 0.0000
451 SLEEP DISORDER 1 0.0000
452 THERAPEUTIC PRODUCT EFFECT INCOMPLETE 1 0.0000
453 OVERDOSE 3 0.0000
454 AGITATION 1 0.0000
455 DYSGEUSIA 1 0.0000
456 ASTHENIA 5 0.0000
457 HALLUCINATION 1 0.0000
458 UNEVALUABLE EVENT 1 0.0000
459 BACK PAIN 3 0.0000
460 CONFUSIONAL STATE 2 0.0000
461 INFLUENZA LIKE ILLNESS 1 0.0000
462 TREMOR 2 0.0000
463 SKIN EXFOLIATION 1 0.0000
464 INTENTIONAL PRODUCT MISUSE 1 0.0000
465 MUSCULOSKELETAL STIFFNESS 1 0.0000
466 MALAISE 5 0.0000
467 OROPHARYNGEAL PAIN 1 0.0000
468 OFF LABEL USE 9 0.0000
469 HAEMOGLOBIN DECREASED 1 0.0000
470 ILLNESS 1 0.0000
471 HAEMORRHAGE 1 0.0000
472 FALL 3 0.0000
473 INFLUENZA 1 0.0000
474 ASTHMA 1 0.0000
475 DEPRESSION 2 0.0000
476 SEIZURE 1 0.0000
477 GENERAL PHYSICAL HEALTH DETERIORATION 1 0.0000
478 DISEASE PROGRESSION 1 0.0000
479 EMOTIONAL DISTRESS 1 0.0000
480 HYPERHIDROSIS 1 0.0000
481 RENAL FAILURE 1 0.0000
482 ARTHRALGIA 3 0.0000
483 HOSPITALISATION 1 0.0000
484 PNEUMONIA 2 0.0000
485 CEREBROVASCULAR ACCIDENT 1 0.0000
486 URINARY TRACT INFECTION 1 0.0000
487 MYOCARDIAL INFARCTION 1 0.0000
488 NASOPHARYNGITIS 1 0.0000
489 GAIT DISTURBANCE 1 0.0000
490 HYPOTENSION 1 0.0000
491 HYPERTENSION 1 0.0000
492 PAIN IN EXTREMITY 1 0.0000
493 CONDITION AGGRAVATED 1 0.0000